Vir Biotechnology, Inc. (VIR) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Rhythm Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc.

CymaBay Therapeutics, Inc.

Merus NV

AbCellera Biologics, Inc.

Vir Biotechnology, Inc.

Maravai Lifesciences Holdings, Inc.

Arcus Biosciences, Inc.

Recursion Pharmaceuticals, Inc.

Summit Therapeutics, Inc.

Why is Vir Biotechnology, Inc. ?

The company has declared Negative results for the last 4 consecutive quarters

OPERATING CASH FLOW(Y) Lowest at USD -457.46 MM
NET PROFIT(HY) At USD -224.09 MM has Grown at -33.98%
ROCE(HY) Lowest at -46.22%

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -13.44%, its profits have fallen by -4%

Reducing Promoter Confidence

Promoters have decreased their stake in the company by -0.71% over the previous quarter and currently hold 14.2% of the company
Promoters decreasing their stake may signify reduced confidence in the future of the business

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -13.44% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Vir Biotechnology, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Vir Biotechnology, Inc.

-26.3%

-0.48

88.35%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-24.03%

EBIT Growth (5y)

-195.10%

EBIT to Interest (avg)

1.09

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.84

Sales to Capital Employed (avg)

0.09

Tax Ratio

0.24%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

85.01%

ROCE (avg)

17.07%

ROE (avg)

12.10%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.72

EV to EBIT

0.22

EV to EBITDA

0.23

EV to Capital Employed

-0.79

EV to Sales

-6.16

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-49.94%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Bearish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company

NET PROFIT(HY)

Higher at USD -224.09 MM

-22What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD -457.46 MM

NET PROFIT(HY)

At USD -224.09 MM has Grown at -33.98%

ROCE(HY)

Lowest at -46.22%

RAW MATERIAL COST(Y)

Grown by 244.87% (YoY

DEBT-EQUITY RATIO (HY)

Highest at -62.48 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 3.06 times

NET SALES(Q)

Lowest at USD 1.21 MM

Here's what is working for Vir Biotechnology, Inc.

Net Profit

Higher at USD -224.09 MM

than preceding 12 month period ended Jun 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Here's what is not working for Vir Biotechnology, Inc.

Net Sales

At USD 1.21 MM has Fallen at -76.72%

over average net sales of the previous four periods of USD 5.22 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (USD MM)

Operating Cash Flow

Lowest at USD -457.46 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Net Profit

At USD -224.09 MM has Grown at -33.98%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Net Sales

Lowest at USD 1.21 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (USD MM)

Debt-Equity Ratio

Highest at -62.48 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio

Lowest at 3.06 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost

Grown by 244.87% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales